FDA½ÓÊÜng28ÄϹ¬Ìá½»µÄÔö²¹ÉúÎïÖÆ¼ÁÐí¿ÉÉêÇë £¬²¢ÊÚÓèLEQEMBI?¹Å°åÉóÅúÓÅÏÈÉóÆÀ×ʸñ

FDA½«ÆÀ¹ÀÑéÖ¤ÐÔIIIÆÚClarity ADÊý¾Ý £¬ÒÔÈ·¶¨ÊÇ·ñ½«LEQEMBI?µÄ¼ÓËÙÉóÅúת»»Îª¹Å°åÉóÅú

ÓÅÏÈÉóÆÀ½«ÓÚ2023Äê7ÔÂ6ÈÕͨ¹ý¡¶´¦·½Ò©Ê¹ÓÃÕ߸¶·Ñ·¨°¸ ¡·(PDUFA) £¬¼ÓËÙFDAµÄÉó²éʱ¼ä

?

ng28ÄϹ¬ÓÚ²³½¡½ñÈÕÐû²¼ £¬ÃÀ¹úʳƷºÍÒ©ÎïÖÎÀí¾Ö(FDA)ÒѽÓÊÜng28ÄϹ¬100mg /mL×¢ÉäÒºLEQEMBI?(lecanemab-irmb)Ôö²¹ÉúÎïÖÆ¼ÁÐí¿ÉÉêÇë(sBLA) £¬ÓÃÓÚ¾²Âö×¢Éä £¬ÒÔÖ§³ÖLEQEMBI¼ÓËÙÉóÅúÏò¹Å°åÉóÅúµÄת±ä¡£LEQEMBI?ÉêÇëÒÑ»ñµÃÓÅÏÈÉóÆÀ×ʸñ £¬´¦·½Ò©Óû§ÊÕ·Ñ·¨°¸(PDUFA)µÄÉúЧÈÕÆÚΪ2023Äê7ÔÂ6ÈÕ¡£FDAĿǰÕý¼Æ»®ÕÙ¿ª×ÉѯίԱ»áÌÖÂÛ¸ÃÉêÇë £¬µ«ÉÐδ¹ûÕæÐû²¼¼¯»áÈÕÆÚ¡£

LEQEMBI?ÊÇÒ»ÖÖÕë¶Ô¾Û¼¯¿ÉÈÜÐÔ(¡°Ô­ÏËά¡±)ºÍ²»ÈÜÐÔµí·ÛÑùÂѰצ£¨A¦Â£©ÐÎʽµÄÈËÔ´»¯ÃâÒßÇòÂѰצÃ1£¨IgG1£©µ¥¿Ë¡¿¹Ìå £¬ÓÚ2023Äê1ÔÂ6ÈÕFDAÔÚ¿ìËÙͨµÀÈ϶¨ÏÂÅú×¼ÓÃÓÚÖÎÁư¢¶û´Äº£Ä¬²¡(AD)¡£LEQEMBI?½öÊÊÓÃÓÚÖÎÁÆÇá¶ÈÈÏÖªÕϰ­»ò´¦ÓÚÇá¶È³Õ´ôÆÚ²¢Ö¤Êµ±£´æA¦Â²¡ÀíµÄ»¼Õß¡£ÔÚLEQEMBI?»ñµÃÅú×¼µ±Ìì £¬ng28ÄϹ¬½«Ñ¸ËÙÏòFDAÌá½»Ôö²¹ÉúÎïÖÆ¼ÁÐí¿ÉÉêÇ루sBLA£© £¬ÒÔ±ãÔڹŰå;¾¶Ï½øÐÐÉóÅú¡£sBLAÊÇ»ùÓÚng28ÄϹ¬×î½üÐû²¼µÄ´óÐÍÈ«ÇòÑéÖ¤ÐÔIIIÆÚÁÙ´²ÊÔÑéClarity ADµÄÑо¿½á¹ûÀ´Ìá½»µÄ¡£LEQEMBI?Âú×ãÖ÷ÒªÖÕµãºÍËùÓÐÒªº¦´ÎÒªÖյ㠣¬½á¹û¾ßÓÐÏÔÖøÍ³¼ÆÑ§ÒâÒå¡£2022Äê11Ô £¬Clarity ADÑо¿µÄ½á¹ûÔÚ°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑé(CTAD)¼¯»áÉÏÐû²¼ £¬²¢Í¬Ê±Ðû²¼ÔÚͬÐÐÆÀÉóµÄҽѧÔÓÖ¾¡¶ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾¡·ÉÏ¡£

LEQEMBI?ÒÑÔÚÃÀ¹ú»ñµÃÅú×¼ £¬²¢ÓÚ2023Äê1ÔÂ18ÈÕÔÚÃÀ¹úÍÆ³ö¡£¸ÃÅú×¼ÊÇ»ùÓÚIIÆÚÊý¾Ý £¬ÕâЩÊý¾Ý±êÃ÷LEQEMBI¼õÉÙÁËA¦Â°ß¿éÔÚ´óÄÔÖеĻýÀÛ £¬ÕâÊÇADµÄÒ»¸ö¾ö¶¨ÐÔÌØÕ÷ £¬Æä¼ÌÐøÅú×¼½«È¡¾öÓÚÔÚÑéÖ¤ÐÔÊÔÑéÖÐÑéÖ¤LEQEMBI?µÄÁÙ´²ÓÅÊÆ¡£FDAÒÑÈ·¶¨Clarity ADµÄ½á¹û¿É×÷ΪÑéÖ¤lecanemabÁÙ´²»ñÒæµÄÑéÖ¤ÐÔÑо¿¡£

LEQEMBI?µÄÈ«Çò¿ª·¢ºÍ¼à¹ÜÌá½»ÓÉng28ÄϹ¬Ö÷µ¼ £¬¶ø²úÆ·ÔòÓÉng28ÄϹ¬ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍÆ¹ã¡£ÆäÖÐ £¬ng28ÄϹ¬ÓµÓÐ×îÖÕ¾ö²ßȨ¡£

 

Contacts
Eisai

MEDIA CONTACT:

Eisai Co., Ltd.

Public Relations Department

TEL: +81 (0)3-3817-5120

 

Eisai Inc. (U.S.)

Libby Holman

+ 1-201-753-1945

Libby_Holman@eisai.com

 

Eisai Europe, Ltd.

(UK, Europe, Australia, New Zealand and Russia)

EMEA Communications Department

+44 (0) 786 601 1272

EMEA-comms@eisai.net

 

INVESTOR CONTACT:

Eisai Co., Ltd.

Investor Relations Department

TEL: +81 (0) 3-3817-5122

Biogen Inc.

 

MEDIA CONTACT:

Natacha Gassenbach

+ 1-857-777-6573

 

public.affairs@biogen.com

 

INVESTOR CONTACT:

Mike Hencke

+ 1-781-464-2442

IR@biogen.com